查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586205

中樞神經系統藥物市場：依藥物類別、疾病、藥物類型、通路分類 - 2025-2030 年全球預測

Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

中樞神經系統藥物市場2023年估值為207.1億美元，預計2024年將達224.4億美元，複合年成長率為9.85%，預計到2030年將達到399.9億美元。

中樞神經系統（CNS）藥物涵蓋了旨在治療影響大腦和脊髓疾病的藥物的重要領域。此領域涵蓋廣泛的藥物，包括神經退化性疾病、精神疾病、疼痛管理等的治療。神經和精神疾病的日益流行、有效治療慢性疼痛的需要以及神經技術的進步推動了對中樞神經系統治療的需求。它具有廣泛的應用範圍，包括阿茲海默症、帕金森氏症、憂鬱症、焦慮症、多發性硬化症和癲癇症，解決未滿足的醫療需求，並提高患者的生活品質。最終用途範圍從醫院、診所到家庭護理，其中受中樞神經系統疾病影響的老年人、兒童和成人人口大量使用。影響該市場的關鍵成長要素包括人口老化、心理健康意識的提高、醫療保健支出的增加以及精準醫療和生物標記識別等技術創新。最近的潛在商機在於生技藥品和基因療法的開發，以及利用人工智慧進行藥物發現和個人化醫療。公司可以透過投資策略夥伴關係關係和研發來利用這些優勢。然而，高昂的研發成本、嚴格的法律規範以及神經學研究的複雜性為市場成長帶來了挑戰。神經保護療法、生物相似藥和增強藥物傳輸系統等領域的創新和研究可能會蓬勃發展，特別是在神經腫瘤學和罕見的中樞神經系統疾病領域。中樞神經系統疾病藥物市場多樣化且快速發展，要求公司在監管環境、競爭環境和數位健康技術整合方面保持領先地位。為了應對這一複雜的情況並實現成長，公司必須優先考慮以患者為中心的方法，投資於尖端研究，並開展合作研究，以加強其治療管道並探索進入新興市場的機會。

主要市場統計
基準年[2023] 207.1億美元
預測年份 [2024] 224.4億美元
預測年份 [2030] 399.9億美元
複合年成長率（%） 9.85%

市場動態：快速發展的中樞神經系統藥物市場的關鍵市場洞察

供需的動態交互作用正在改變中樞神經系統藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球神經病變和認知障礙的發生率不斷增加
    • 增加政府計劃和宣傳活動，以傳播有關神經系統危險因素和症狀的知識
    • 患有神經系統併發症的老年人口不斷增加
  • 市場限制因素
    • 藥物發現和開發需要昂貴的資本投資和充足的基礎設施。
  • 市場機會
    • 持續的藥物研發以滿足精神病學和神經科特定的不斷變化的需求
    • 在中樞神經系統藥物發現中採用人工智慧和機器學習
  • 市場挑戰
    • 嚴格的產品核可規定和對產品召回的擔憂
    • 儘管有足夠的研究，但缺乏神經病學領域的專業知識

波特五力：駕馭中樞神經系統藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對中樞神經系統藥物市場的影響

外部宏觀環境因素在塑造中樞神經系統藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解中樞神經系統藥物市場的競爭狀況

中樞神經系統藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣中樞神經系統藥物市場供應商的績效評估

FPNV 定位矩陣是評估中樞神經系統藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了中樞神經系統藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，中樞神經系統藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球神經和認知障礙的發生率不斷增加
      • 增加政府計劃和宣傳活動，以傳播有關神經系統危險因素和症狀的知識
      • 患有神經系統併發症的老年人口不斷增加
    • 抑制因素
      • 藥物發現和開發需要大量資本投資和適當的基礎設施
    • 機會
      • 持續藥物開發以滿足精神病學和神經病學領域獨特且不斷變化的需求
      • 中樞神經系統藥物發現中引入人工智慧和機器學習
    • 任務
      • 嚴格的產品核可規定和對產品召回的擔憂
      • 儘管有足夠的研究，但缺乏神經病學領域的主題專業知識
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的中樞神經系統藥物市場

  • 止痛藥
  • 麻醉劑
  • 抗癲癇藥
  • 抗帕金森氏症藥物
  • 抗憂鬱症

第7章依疾病分類的中樞神經系統藥物市場

  • 中樞神經系統創傷
  • 感染疾病
  • 心理健康
  • 神經退化性疾病
  • 神經血管疾病

第8章中樞神經系統藥物市場（依藥物類型）

  • 生物製藥
  • 非生技藥品

第9章中樞神經系統藥物市場：依分銷管道分類

  • 醫院藥房
  • 線上
  • 零售藥房

第10章美洲中樞神經系統藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太中樞神經系統藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲中樞神經系統藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Astex 和卡迪夫大學宣布合作發現新藥
    • Newlux Farm 宣布完成對賽諾菲現有產品的收購
    • Precision Life 與工業建立中樞神經系統疾病多標靶夥伴關係
    • 合作將重點放在中樞神經系統疾病的治療目標
    • Intrinsic Medicine 與 Phoenix Biotech 簽署合併協議
    • Solid Biosciences 宣佈在收購 AavantiBio 的同時進行 7,500 萬美元私募
    • Gencyc開始開發合作
    • IAMA Therapeutics 與義大利理工學院合作，進行神經科學藥物發現的突破性研究。
    • 艾伯維 (AbbVie) 和 Gedeon Richter 宣佈在神經精神疾病領域開展合作
    • 艾伯維 (AbbVie) 收購 Syndesi Therapeutics 以加強神經科學產品組合
  • 戰略分析和建議

公司名單

  • AN Pharmacia Laboratories Pvt. Ltd.
  • AbbVie Inc.
  • Alkermes PLC
  • Apotex Inc.
  • Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma
  • BIAL-PORTELA & CA, SA
  • Biogen Inc.
  • Catalent, Inc.
  • CNS Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Divi's Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • East India Pharmaceutical Works Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International PLC by DuPont de Nemours, Inc.
  • Eridanus Healthcare
  • EVERSANA
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Intas Pharmaceuticals Ltd.
  • Jabs Biotech Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • La Renon Healthcare Pvt. Ltd.
  • Lupin Ltd.
  • Merck & Co.
  • Micro Labs Ltd.
  • Midas Pharma GmbH
  • Neuracle Lifesciences Private Limited
  • Neurocon Inc.
  • Novartis Group
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Priavoid GmbH
  • Reliance Formulations Pvt. Ltd.
  • Sanofi SA
  • Servier Laboratories（Aust）Pty Ltd
  • Shine Pharmaceuticals Ltd.
  • Somacare
  • SteriMax Inc.
  • Sun Pharmaceuticals Pvt Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB SA
  • Wellona Pharma
  • Zee Laboratories Limited
Product Code: MRR-434CCDA05199

The Central Nervous System Drugs Market was valued at USD 20.71 billion in 2023, expected to reach USD 22.44 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 39.99 billion by 2030.

Central Nervous System (CNS) Drugs encompass a critical domain within pharmaceuticals aimed at treating disorders affecting the brain and spinal cord. This segment covers a broad range of medications, including treatments for neurodegenerative diseases, mental health disorders, and pain management. The necessity for CNS drugs is driven by the growing prevalence of neurological and psychiatric conditions, the need for effective management of chronic pain, and advancements in neurotechnology. Applications range across Alzheimer's, Parkinson's, depression, anxiety, multiple sclerosis, and epilepsy, addressing unmet medical needs and enhancing patient quality of life. The end-use scope extends to hospitals, clinics, and home care settings, with significant uptake from geriatric, pediatric, and adult populations impacted by CNS disorders. Key growth factors influencing this market include an aging demographic, increased mental health awareness, rising healthcare expenditures, and technological innovations such as precision medicine and biomarker identification. Recent potential opportunities lie in developing biologics, gene therapies, and leveraging artificial intelligence for drug discovery and personalized medicine. Companies can capitalize on these by investing in strategic partnerships and R&D. However, market growth is challenged by high R&D costs, stringent regulatory frameworks, and the complexity of neurological research, which result in longer timelines and uncertain outcomes. Innovation and research can thrive in areas like neuroprotective therapies, biosimilars, and enhancing drug delivery systems, particularly within neuro-oncology and rare CNS disorders. The CNS drugs market is diverse and rapidly evolving, requiring businesses to stay ahead of regulatory landscapes, competitive dynamics, and the integration of digital health technologies. To navigate these complexities and capitalize on growth, firms must prioritize patient-centric approaches, invest in cutting-edge research, and explore collaborations that enhance therapeutic pipelines and access to emerging markets.

KEY MARKET STATISTICS
Base Year [2023] USD 20.71 billion
Estimated Year [2024] USD 22.44 billion
Forecast Year [2030] USD 39.99 billion
CAGR (%) 9.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Drugs Market

The Central Nervous System Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of neurological and cognitive disorders across the globe
    • Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
    • Rise in geriatric population with neurological complications
  • Market Restraints
    • Requirement of high capital investment and adequate infrastructure for drug discovery and development
  • Market Opportunities
    • Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
    • Adoption of artificial intelligence and machine learning in CNS drug discovery
  • Market Challenges
    • Stringent regulations for product approvals and concern regarding product recalls
    • Dearth of subject expertise in the neurological field amid the competent studies

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Drugs Market

A detailed market share analysis in the Central Nervous System Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Drugs Market

A strategic analysis of the Central Nervous System Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Apotex Inc., Arvelle Therapeutics International GmbH by Angelini Pharma Inc., AstraZeneca PLC, Aurobindo Pharma, BIAL - PORTELA & CA, S.A., Biogen Inc., Catalent, Inc., CNS Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., East India Pharmaceutical Works Ltd., Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC by DuPont de Nemours, Inc., Eridanus Healthcare, EVERSANA, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intas Pharmaceuticals Ltd., Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Merck & Co., Micro Labs Ltd., Midas Pharma GmbH, Neuracle Lifesciences Private Limited, Neurocon Inc., Novartis Group, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Priavoid GmbH, Reliance Formulations Pvt. Ltd., Sanofi S.A., Servier Laboratories (Aust) Pty Ltd, Shine Pharmaceuticals Ltd., Somacare, SteriMax Inc., Sun Pharmaceuticals Pvt Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., UCB S.A., Wellona Pharma, and Zee Laboratories Limited.

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Classes, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, and Antidepressant.
  • Based on Diseases, market is studied across CNS Trauma, Infectious Diseases, Mental Health, Neurodegenerative Diseases, and Neurovascular Diseases.
  • Based on Drug Type, market is studied across Biologics and Non-Biologics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
      • 5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
      • 5.1.1.3. Rise in geriatric population with neurological complications
    • 5.1.2. Restraints
      • 5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
      • 5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
      • 5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Central Nervous System Drugs Market, by Drug Classes

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Anesthetics
  • 6.4. Anti-Epileptics
  • 6.5. Anti-Parkinson Drugs
  • 6.6. Antidepressant

7. Central Nervous System Drugs Market, by Diseases

  • 7.1. Introduction
  • 7.2. CNS Trauma
  • 7.3. Infectious Diseases
  • 7.4. Mental Health
  • 7.5. Neurodegenerative Diseases
  • 7.6. Neurovascular Diseases

8. Central Nervous System Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Non-Biologics

9. Central Nervous System Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online
  • 9.4. Retail Pharmacies

10. Americas Central Nervous System Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Central Nervous System Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Astex and Cardiff University announce drug discovery collaboration
    • 13.3.2. Neuraxpharm announces closing of acquisition of established products from Sanofi
    • 13.3.3. PrecisionLife and Ono sign multi-target partnership for CNS disorders
    • 13.3.4. Collaboration will focus on therapy targets for CNS disorders
    • 13.3.5. Intrinsic Medicine enters merger deal with Phoenix Biotech
    • 13.3.6. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
    • 13.3.7. Gensaic enters into collaboration to develop
    • 13.3.8. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
    • 13.3.9. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
    • 13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A. N. Pharmacia Laboratories Pvt. Ltd.
  • 2. AbbVie Inc.
  • 3. Alkermes PLC
  • 4. Apotex Inc.
  • 5. Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
  • 6. AstraZeneca PLC
  • 7. Aurobindo Pharma
  • 8. BIAL - PORTELA & CA, S.A.
  • 9. Biogen Inc.
  • 10. Catalent, Inc.
  • 11. CNS Pharmaceuticals, Inc.
  • 12. Daiichi Sankyo Company, Limited
  • 13. Divi's Laboratories Ltd.
  • 14. Dr. Reddy's Laboratories Ltd.
  • 15. East India Pharmaceutical Works Ltd.
  • 16. Eisai Co., Ltd.
  • 17. Eli Lilly and Company
  • 18. Endo International PLC by DuPont de Nemours, Inc.
  • 19. Eridanus Healthcare
  • 20. EVERSANA
  • 21. F. Hoffmann-La Roche AG
  • 22. GlaxoSmithKline PLC
  • 23. H. Lundbeck A/S
  • 24. Intas Pharmaceuticals Ltd.
  • 25. Jabs Biotech Pvt. Ltd.
  • 26. Johnson & Johnson Services, Inc.
  • 27. La Renon Healthcare Pvt. Ltd.
  • 28. Lupin Ltd.
  • 29. Merck & Co.
  • 30. Micro Labs Ltd.
  • 31. Midas Pharma GmbH
  • 32. Neuracle Lifesciences Private Limited
  • 33. Neurocon Inc.
  • 34. Novartis Group
  • 35. Otsuka Pharmaceutical Co., Ltd.
  • 36. Pfizer Inc.
  • 37. Priavoid GmbH
  • 38. Reliance Formulations Pvt. Ltd.
  • 39. Sanofi S.A.
  • 40. Servier Laboratories (Aust) Pty Ltd
  • 41. Shine Pharmaceuticals Ltd.
  • 42. Somacare
  • 43. SteriMax Inc.
  • 44. Sun Pharmaceuticals Pvt Ltd.
  • 45. Takeda Pharmaceutical Co. Ltd.
  • 46. Teva Pharmaceutical Industries Ltd.
  • 47. Torrent Pharmaceuticals Ltd.
  • 48. UCB S.A.
  • 49. Wellona Pharma
  • 50. Zee Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023